From a practical standpoint, the two phrases mean essentially the same thing.
They actually don't in cases where newer therapies increase tolerability and have higher therapeutic indexes. Proving either is not necessarily a quicker path to approval. The difference between the two phrases is likely to grow over time (couple decades) as pharmacoeconomics works into the equation.
Unless otherwise indicated, this is the personal viewpoint of David Miller and not necessarily that of Biotech Stock Research, LLC. We're on Twitter at BiotechStockRsr
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.